Torax Medical’s Linx System: A New Approach To GERD

Although many companies have fallen short in developing a truly effective minimally invasive device for the treatment of chronic GERD, Torax Medical’s co-founder, president, and CEO Todd Berg believes the company’s new Linx Reflux Management System will find success because it is fundamentally unlike anything else that has come before. In an interview with Medtech Insight, Berg discussed the Linx device, the GERD market, and the company’s strategies for success.

Most of the 20 million adults in the US who suffer from chronic gastroesophageal reflux disease (GERD) hope to find symptomatic relief from their “heartburn” with first-line nonsurgical treatments, like raising the head of the bed, losing weight, eating smaller meals, or taking medications such as antacids or proton-pump inhibitors (PPIs). However, despite high-dose medications, GERD-related symptoms persist in almost 40% of patients, and less than 1% of these patients resort to having a laparoscopic Nissen fundoplication, an invasive, but effective surgical procedure that involves wrapping the upper portion of the stomach or fundus around the bottom of the esophagus.

Over the last decade, medical device manufacturers have been trying to develop an effective minimally invasive device for the treatment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By 

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.